Bluejay completes site milestone: what it means for Bluejay Diagnostics stock

Published on 10/14/2026 at 06:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 13 filing cites an October 23 contractual deadline. For Bluejay Diagnostics stock, a 20-minute design remains tied to regulatory work.

Manufacturing and clinical timeline

The October 13 filing described a completed cartridge manufacturing site ahead of the October 23 deadline.
Bluejay's October 6 study update covered 777 evaluable patients and 140 non-survivors.
Bluejay Diagnostics stock was last at USD 0.83 on Nasdaq on October 13, 2026.

Bluejay, US0956336087, Illustration mit AI erstellt.

Bluejay Diagnostics (US0956336087) completed a manufacturing-site milestone on October 13, 2026, bringing its Symphony cartridge program ahead of an October 23 contractual deadline. For Bluejay Diagnostics stock, the announcement matters because production readiness is advancing while the Symphony IL-6 test remains an investigational device.

Three dated steps in development

On August 13, 2026, Bluejay reported second-quarter 2026 results with USD 9.6 million in cash and a USD 4.24 million net loss for the first six months of 2026, according to Worcester Business Journal.

On October 6, 2026, Newswire reported that the SYMON-II analysis included 777 evaluable patients, including 140 non-survivors and 637 survivors at 28 days. On October 13, 2026, Bluejay completed the manufacturing site under its Toray agreement, as detailed by StockTitan.

What does the milestone change?

The new site at SanyoSeiko in Japan adds a manufacturing pathway alongside Bluejay's U.S. relationship with ALURIS Sciences. The company says the arrangement is intended to improve operational flexibility as it prepares a regulatory submission.

The commercial case remains conditional. The Symphony IL-6 test has not received FDA clearance and cannot be marketed for commercial clinical use in the United States, while the SYMON-II baseline data do not establish sensitivity, specificity or regulatory acceptability.

The next dated operational marker

The next explicit date is October 23, 2026, the contractual deadline under the amended Toray license agreement. Bluejay's first product candidate is designed for a sample-to-result process of 20 minutes, but the regulatory pathway still depends on further clinical analysis and a planned 510(k) submission.

Nasdaq quote stays dated

The last available home-exchange quote was USD 0.83 on Nasdaq on October 13, 2026 at 4:00 p.m. ET. The Nasdaq listing is identified as BJDX, and the company operates in healthcare medical devices.

Market context: Market report Nasdaq Composite.